FindTrial
Sign In

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with Atrial Fibrillation in the very elderly

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with Atrial Fibrillation in the very elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-16009261
Enrollment
Unknown
Registered
2016-09-24
Start date
2016-10-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

Case series:warfarin daily dose

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
80 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Han-Chinese patients; 2. Ageed overy 80 years; 3. Patients with permanent atrial fibrillation; 4. Taking Warfarin with stable INR and dosage (there is no acute diseases in recent 2months); 5. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Inherited warfarin resistance; 2. End-stage diseases with expected life time < 1 year; 3. blood diseases; Cachexia; Active cancer; fever;Collagen angiopathy; Liver disease; Malnutrition; Infectious Hepatitis; Diarrhea; Jaudice; Vitamin K insufficiency etc.; 4. Uncontrolled hyperlipidemia; Thyroid dysfunction; Nephrotic syndrom; 5. Combined other anticoagulant; 6. All subjects were related to each other and the history of intermarriage.

Design outcomes

Primary

MeasureTime frame
Warfarin Dosage per day;Kidney Function;Liver Function;Heart Function;Hemorrage Events;Thrombotic Events;Medications;—

Countries

China

Contacts

Public ContactLi Xiaoying

Chinese PLA General Hospital

xyli301@163.com+86 010 66876271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026